ClinicalTrials.gg
Active, not recruitingNCT07027527Updated Oct 13, 2026

An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis

A Phase 1 interventional study of APG777 and APG990 in Atopic Dermatitis, sponsored by Apogee Therapeutics, Inc.. Active, not recruiting at 20 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Apogee Therapeutics, Inc. (part of AbbVie) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Dermatitis, Atopic by AbbVie — 3 open to participants now, 12 under way, 4 of them phase 3. Dermatitis, Atopic · AbbVie.

Enrollment
16th of 22
86 · median 228
Started
2025
with 1 other
Phase 1
3 of 34
none open now
Primary completion
2026-08
later than 1 of 11 live
Registered
33rd of 34
by date

Among the 34 studies in Dermatitis, Atopic by AbbVie, this one is the 16th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 in phase 1, reaches primary completion later than 1 of the 11 other live ones, and was the 33rd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 34 studies in Dermatitis, Atopic by AbbVie are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Dermatitis, Atopic by AbbVie, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic (PK) parameters of the combination of APG777 + APG990 in adults with moderate-to-severe atopic dermatitis (AD), in comparison to dupilumab. The duration of the study will be approximately 82 weeks for each participant and will consist of a Screening Period (up to 6 weeks), Treatment Period (Baseline-Week 24), and Follow-up Period (Week 28-Week 76).

Read the detailed description

Participants will be randomized to APG777 + APG990 or dupilumab in a 1:1 ratio. Randomization will be stratified on Day 1 according to Baseline disease severity and geographic region.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Atopic Dermatitis
  • Moderate-to-Severe AD
  • APG777
  • Dupilumab
  • APG990
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of AD that has been present for ≥ 1 year prior to the Screening visit and as determined by the Investigator through participant interview and/or review of the medical history.
  • Moderate-to-severe AD at Screening and Baseline (Day 1) visits, defined as: a) Eczema Area and Severity Index (EASI) score of ≥ 16, b) vIGA-AD score of ≥ 3, and c) AD affecting ≥10% of body surface area (BSA).
  • History of inadequate response to treatment with topical medications
  • Women of must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline (Day 1) visit.

Exclusion criteria

Exclusion Criteria

  • Participation in a prior study with APG777 or APG990.
  • Prior treatment with protocol-specified monoclonal antibodies (mAbs).
  • Has used any AD-related topical medications within 7 days prior to Baseline visit.
  • Has used systemic treatments (other than biologics) and/or phototherapies and/or laser therapy that could affect AD within 4 weeks prior to Baseline visit
  • History of known to any of the ingredients in APG777, APG990, or dupilumab.
  • Presence of dermatologic conditions and/or comorbidities that might confound the diagnosis of AD and/or might interfere with study assessments

Note: Additional protocol defined Inclusion/Exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    APG777 + APG990

    Participants will receive protocol specified combination dose of APG777 + APG990

    Drug: APG777 · Drug: APG990

  • Active comparator
    Dupilumab

    Participants will receive protocol specified dose of Dupilumab

    Drug: Dupilumab

Interventions

  • DrugAPG777

    Subcutaneous (SC) injection

  • DrugAPG990

    SC injection

  • SC injection

    Also known as: Dupixent

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Predose Serum Concentrations (Ctrough) of APG777

    PK parameters will be performed using a non-compartmental approach with a validated PK software.

    Time frame: Baseline, Week 1, 2, 4, 8, 12, 16, 20, 24

  2. Predose Serum Concentrations (Ctrough) of APG990

    PK parameters will be performed using a non-compartmental approach with a validated PK software.

    Time frame: Baseline, Week 1, 2, 4, 8, 12, 16, 20, 24

  3. Maximum Serum Concentrations (Cmax) of APG777

    PK parameters will be performed using a non-compartmental approach with a validated PK software

    Time frame: Baseline, Week 1, 2, 4, 8, 12, 16, 20, 24

  4. Maximum Serum Concentrations (Cmax) of APG990

    PK parameters will be performed using a non-compartmental approach with a validated PK software.

    Time frame: Baseline, Week 1, 2, 4, 8, 12, 16, 20, 24

  5. Time to Reach Cmax (tmax) of APG777

    PK parameters will be performed using a non-compartmental approach with a validated PK software. If the maximum value occurs at more than one time point, tmax is defined as the first time point with this value.

    Time frame: Baseline, Week 1, 2, 4, 8, 12, 16, 20, 24

  6. Time to Reach Cmax (tmax) of APG990

    PK parameters will be performed using a non-compartmental approach with a validated PK software. If the maximum value occurs at more than one time point, tmax is defined as the first time point with this value.

    Time frame: Baseline, Week 1, 2, 4, 8, 12, 16, 20, 24

07

Study locations

20 sites
  • Investigational Site
    Darlinghurst, New South Wales 2010, Australia
  • Investigational Site
    Kogarah, New South Wales 2217, Australia
  • Investigational Site
    Westmead, New South Wales 2145, Australia
  • Investigational Site
    Woolloongabba, Queensland 4102, Australia
  • Investigational Site
    Carlton, Victoria 3053, Australia
  • Investigational Site
    East Melbourne, Victoria 3002, Australia
  • Investigational Site
    Mitcham, Victoria 3132, Australia
  • Investigational Site
    Parkville, Victoria 3050, Australia
  • Investigational Site
    Fremantle, Western Australia 6160, Australia
  • Investigational Site
    London, Ontario N6H 5L5, Canada
  • Investigational Site
    Peterborough, Ontario K9J 5K2, Canada
  • Investigational Site
    Richmond Hill, Ontario L4B 1A5, Canada
  • Investigational Site
    Toronto, Ontario M4E 1R7, Canada
  • Investigational Site
    Toronto, Ontario M4W 2N4, Canada
  • Investigational Site
    Toronto, Ontario M5A 3R6, Canada
  • Investigational Site
    Montreal, Quebec H1Y 3L1, Canada
  • Investigational Site
    Québec, Quebec G1W 1S2, Canada
  • Investigational Site
    Sherbrooke, Quebec J1G 1X9, Canada
  • Investigational Site
    Hamilton, Waitako 3204, New Zealand
  • Investigational Site
    Auckland, 1051, New Zealand
08

References and documents

Publications

  • Lim XQ, Winter E, Nograles K, Xu J, Zhang ZQ, Thankamony S, Dillinger L, Dambkowski CL. A First-in-Human, Single- and Multiple-Dose Study of APG777, a Half-Life-Extended Anti-IL-13 Monoclonal Antibody, in Healthy Volunteers. Clin Transl Sci. 2025 Dec;18(12):e70456. doi: 10.1111/cts.70456. PubMed 41422501 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Aug 2026, 14 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 14 months is above that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2025
First posted
Jun 18, 2025
StartActual
Jun 4, 2025
Primary completionActual
Aug 29, 2026
CompletionEst.
Dec 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and contact details
2 updates, last Oct 13, 2026
Show all 2 updates
  1. Oct 13, 2026
    Minor edits only
    + 1 other change: contact details
  2. Oct 7, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07027527
Responsible party
Sponsor
First posted
Jun 18, 2025
Start date
Jun 4, 2025
Primary completion
Aug 29, 2026
Completion
Dec 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zumilokibart

Start the discussion